Calidi Biotherapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: CLDWW · Form: 8-K · Filed: Apr 1, 2025 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: CLDI
TL;DR
Calidi Biotherapeutics signed a big deal and sold some stock on March 28th.
AI Summary
On March 28, 2025, Calidi Biotherapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial position and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- March 28, 2025 (date) — Date of earliest event reported
- First Light Acquisition Group, Inc. (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by Calidi Biotherapeutics?
The filing states that Calidi Biotherapeutics, Inc. entered into a material definitive agreement on March 28, 2025, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold on an unregistered basis?
The filing mentions unregistered sales of equity securities on March 28, 2025, but does not specify the type or amount of securities sold.
When was Calidi Biotherapeutics, Inc. formerly known as First Light Acquisition Group, Inc.?
The date of the name change from First Light Acquisition Group, Inc. to Calidi Biotherapeutics, Inc. was April 6, 2021.
What is the SIC code for Calidi Biotherapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Calidi Biotherapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Where is Calidi Biotherapeutics, Inc. headquartered?
Calidi Biotherapeutics, Inc. is headquartered in San Diego, California, with a business address at 4475 Executive Drive, Suite 200, San Diego, CA 92121.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 1, 2025 regarding Calidi Biotherapeutics, Inc. (CLDWW).